Indirubin-pregnane X receptor-JNK axis accelerates skin wound healing.
Animals
Cell Line
Cell Movement
/ physiology
Cell Proliferation
/ physiology
Cytochrome P-450 CYP1A1
/ metabolism
Female
Humans
Indoles
/ metabolism
Keratinocytes
/ metabolism
MAP Kinase Signaling System
/ physiology
Mice
Mice, Inbred BALB C
Pregnane X Receptor
/ metabolism
RNA, Messenger
/ metabolism
Receptors, Aryl Hydrocarbon
/ metabolism
Signal Transduction
/ physiology
Skin
/ metabolism
Transcriptional Activation
/ physiology
Wound Healing
/ physiology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 12 2019
03 12 2019
Historique:
received:
21
06
2019
accepted:
18
11
2019
entrez:
5
12
2019
pubmed:
5
12
2019
medline:
4
11
2020
Statut:
epublish
Résumé
Indirubin is a potent anti-inflammatory phytochemical derived from indigo naturalis. It is also endogenously produced in the intestine and detected in the circulation in mammals. Indirubin exerts its biological functions via two xenobiotic receptor systems: aryl hydrocarbon receptor (AHR) and pregnane X receptor (PXR); however, its effects on wound healing remain elusive. To investigate whether indirubin promotes wound healing, we utilized an in vitro scratch injury assay and in vivo full-thickness mouse skin ulcer model and assessed wound closure. Indirubin significantly accelerated wound closure in both the scratch assay and the skin ulcer model. Using inhibitors of cell proliferation or migration, indirubin was found to upregulate the migratory but not the proliferative capacity of keratinocytes. Activation of AHR/PXR by indirubin was confirmed by their nuclear translocation and subsequent upregulation of CYP1A1 (AHR), or UGT1A1 mRNA (PXR) and also by luciferase reporter assay (PXR). Although both AHR and PXR were activated by indirubin, its pro-migratory capacity was canceled by PXR inhibition but not by AHR inhibition and was dependent on the JNK pathway. Moreover, activated PXR was detected in the nuclei of re-epithelialized keratinocytes in human skin ulcers. In conclusion, this study shows that the indirubin-PXR-JNK pathway promotes skin wound healing.
Identifiants
pubmed: 31796845
doi: 10.1038/s41598-019-54754-2
pii: 10.1038/s41598-019-54754-2
pmc: PMC6890704
doi:
Substances chimiques
Indoles
0
Pregnane X Receptor
0
RNA, Messenger
0
Receptors, Aryl Hydrocarbon
0
Cytochrome P-450 CYP1A1
EC 1.14.14.1
indirubin
V86L8P74GI
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18174Références
Anal Bioanal Chem. 2010 Mar;396(6):2251-63
pubmed: 20145913
Cell. 1995 Dec 15;83(6):835-9
pubmed: 8521507
J Dermatol Sci. 2012 Jan;65(1):70-2
pubmed: 22051056
Endocr Rev. 2002 Oct;23(5):687-702
pubmed: 12372848
Br J Dermatol. 2018 Jan;178(1):124-131
pubmed: 28815560
Eur J Pharm Sci. 2014 May 13;55:12-9
pubmed: 24486481
Acta Histochem. 2016 Jul;118(6):606-614
pubmed: 27396532
Science. 2001 Jun 22;292(5525):2329-33
pubmed: 11408620
J Biol Chem. 2011 Feb 4;286(5):3570-8
pubmed: 21127053
J Pharmacol Exp Ther. 2006 Oct;319(1):488-96
pubmed: 16857728
Arch Dermatol Res. 2014 Nov;306(9):769-79
pubmed: 24966027
Nucleic Acids Res. 2009 Mar;37(4):1160-73
pubmed: 19129222
Zhongguo Zhong Yao Za Zhi. 2010 May;35(9):1148-51
pubmed: 20707071
Appl Biochem Biotechnol. 2014 Mar;172(6):3194-206
pubmed: 24500796
Clin Microbiol Rev. 2012 Jan;25(1):106-41
pubmed: 22232373
J Dermatol Sci. 2018 Jun;90(3):284-294
pubmed: 29500077
Chem Pharm Bull (Tokyo). 2006 Sep;54(9):1239-43
pubmed: 16946527
J Dermatol Sci. 2012 Aug;67(2):140-6
pubmed: 22721997
J Dermatol Sci. 2009 Jun;54(3):168-74
pubmed: 19303259
J Gastroenterol. 2016 Sep;51(9):853-61
pubmed: 27160749
Biochem Biophys Res Commun. 1999 Nov 19;265(2):469-72
pubmed: 10558891
Cell Rep. 2017 Nov 21;21(8):2277-2290
pubmed: 29166616
Biochemistry. 2000 Nov 14;39(45):13817-24
pubmed: 11076521
Cell. 2011 Oct 28;147(3):629-40
pubmed: 21999944
Immunity. 2018 Aug 21;49(2):353-362.e5
pubmed: 30119997
J Ethnopharmacol. 2013 Jan 9;145(1):214-9
pubmed: 23149289
Br J Dermatol. 2018 Sep;179(3):800
pubmed: 29791716
Neoplasma. 2015;62(2):209-29
pubmed: 25591586
Br J Dermatol. 2001 Nov;145(5):749-57
pubmed: 11736898
J Cell Sci. 2009 Jun 1;122(Pt 11):1823-33
pubmed: 19435800
J Invest Dermatol. 2013 Aug;133(8):2023-30
pubmed: 23448877
Oncotarget. 2017 May 30;8(22):36658-36663
pubmed: 28525368
Nature. 2000 Jul 27;406(6794):435-9
pubmed: 10935643
Drug Metab Pharmacokinet. 2016 Apr;31(2):139-45
pubmed: 26987505
Mol Immunol. 2018 Sep;101:386-395
pubmed: 30064075
Inflammation. 2017 Feb;40(1):1-12
pubmed: 27718095
PLoS One. 2011;6(9):e25143
pubmed: 21949871
Biosci Rep. 2018 Nov 23;38(6):
pubmed: 30341238
J Dermatol Sci. 2015 Nov;80(2):83-8
pubmed: 26276439
Drug Metab Dispos. 2018 Apr;46(4):397-404
pubmed: 29440179
Braz J Med Biol Res. 2018 Oct 18;51(12):e7862
pubmed: 30365726
Sci Rep. 2017 Jun 16;7(1):3635
pubmed: 28623334
Endocr Rev. 1999 Oct;20(5):689-725
pubmed: 10529899
Cell Tissue Res. 2016 Jul;365(1):85-99
pubmed: 26888423
Biochem Pharmacol. 2001 Sep 15;62(6):777-86
pubmed: 11551524
J Invest Dermatol. 2017 Oct;137(10):2217-2226
pubmed: 28552542
Onco Targets Ther. 2018 May 18;11:2937-2944
pubmed: 29849463
J Biol Chem. 2001 Aug 24;276(34):31475-8
pubmed: 11425848